Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 21

Cited In for PubMed (Select 15588746)

1.

Paroxetine versus other anti-depressive agents for depression.

Cipriani A, Furukawa TA, Veronese A, Watanabe N, Churchill R, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2007;(2). pii: CD006531.

2.

Venlafaxine versus other anti-depressive agents for depression.

Cipriani A, Signoretti A, Furukawa TA, Churchill R, Tomelleri S, Omori IM, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2007;(2). pii: CD006530.

3.

Characteristics of randomized trials published in Latin America and the Caribbean according to funding source.

Reveiz L, Sangalang S, Glujovsky D, Pinzon CE, Asenjo Lobos C, Cortes M, Cañón M, Bardach A, Bonfill X.

PLoS One. 2013;8(2):e56410. doi: 10.1371/journal.pone.0056410. Epub 2013 Feb 13. Review.

4.

SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials.

Chan AW, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA, Dickersin K, Hróbjartsson A, Schulz KF, Parulekar WR, Krleza-Jeric K, Laupacis A, Moher D.

BMJ. 2013 Jan 8;346:e7586. doi: 10.1136/bmj.e7586.

5.

Duloxetine versus other anti-depressive agents for depression.

Cipriani A, Koesters M, Furukawa TA, Nosè M, Purgato M, Omori IM, Trespidi C, Barbui C.

Cochrane Database Syst Rev. 2012 Oct 17;10:CD006533. doi: 10.1002/14651858.CD006533.pub2. Review.

6.

Where Does Evidence from New Trials for Schizophrenia Fit with the Existing Evidence: A Case of the Emperor's New Clothes?

Jayaram M, Rattehalli RD, Adams CE.

Schizophr Res Treatment. 2012;2012:625738. doi: 10.1155/2012/625738. Epub 2012 Apr 8.

7.

Citalopram versus other anti-depressive agents for depression.

Cipriani A, Purgato M, Furukawa TA, Trespidi C, Imperadore G, Signoretti A, Churchill R, Watanabe N, Barbui C.

Cochrane Database Syst Rev. 2012 Jul 11;7:CD006534. doi: 10.1002/14651858.CD006534.pub2. Review.

8.

Association of industry funding with the outcome and quality of randomized controlled trials of drug therapy for rheumatoid arthritis.

Khan NA, Lombeida JI, Singh M, Spencer HJ, Torralba KD.

Arthritis Rheum. 2012 Jul;64(7):2059-67. doi: 10.1002/art.34393.

9.
10.

Mirtazapine versus other antidepressive agents for depression.

Watanabe N, Omori IM, Nakagawa A, Cipriani A, Barbui C, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2011 Dec 7;(12):CD006528. doi: 10.1002/14651858.CD006528.pub2. Review.

11.

Industry and evidence-based medicine: Believable or conflicted? A systematic review of the surgical literature.

Bailey CS, Fehlings MG, Rampersaud YR, Hall H, Wai EK, Fisher CG.

Can J Surg. 2011 Oct;54(5):321-6. doi: 10.1503/cjs.008610. Review.

12.

Cognitive control deficits in schizophrenia: mechanisms and meaning.

Lesh TA, Niendam TA, Minzenberg MJ, Carter CS.

Neuropsychopharmacology. 2011 Jan;36(1):316-38. doi: 10.1038/npp.2010.156. Epub 2010 Sep 15. Review.

13.

The financing of drug trials by pharmaceutical companies and its consequences. Part 1: a qualitative, systematic review of the literature on possible influences on the findings, protocols, and quality of drug trials.

Schott G, Pachl H, Limbach U, Gundert-Remy U, Ludwig WD, Lieb K.

Dtsch Arztebl Int. 2010 Apr;107(16):279-85. doi: 10.3238/arztebl.2010.0279. Epub 2010 Apr 23. Review.

14.

Sertraline versus other antidepressive agents for depression.

Cipriani A, La Ferla T, Furukawa TA, Signoretti A, Nakagawa A, Churchill R, McGuire H, Barbui C.

Cochrane Database Syst Rev. 2010 Apr 14;(4):CD006117. doi: 10.1002/14651858.CD006117.pub4. Review.

15.

Reporting bias in medical research - a narrative review.

McGauran N, Wieseler B, Kreis J, Schüler YB, Kölsch H, Kaiser T.

Trials. 2010 Apr 13;11:37. doi: 10.1186/1745-6215-11-37. Review.

16.

Fluvoxamine versus other anti-depressive agents for depression.

Omori IM, Watanabe N, Nakagawa A, Cipriani A, Barbui C, McGuire H, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006114. doi: 10.1002/14651858.CD006114.pub2. Review.

17.

Milnacipran versus other antidepressive agents for depression.

Nakagawa A, Watanabe N, Omori IM, Barbui C, Cipriani A, McGuire H, Churchill R, Furukawa TA.

Cochrane Database Syst Rev. 2009 Jul 8;(3):CD006529. doi: 10.1002/14651858.CD006529.pub2. Review.

18.

Escitalopram versus other antidepressive agents for depression.

Cipriani A, Santilli C, Furukawa TA, Signoretti A, Nakagawa A, McGuire H, Churchill R, Barbui C.

Cochrane Database Syst Rev. 2009 Apr 15;(2):CD006532. doi: 10.1002/14651858.CD006532.pub2. Review.

19.

Who are the new users of antipsychotic medications?

Domino ME, Swartz MS.

Psychiatr Serv. 2008 May;59(5):507-14. doi: 10.1176/appi.ps.59.5.507.

20.

Rethinking antipsychotic formulary policy.

Rosenheck RA, Leslie DL, Busch S, Rofman ES, Sernyak M.

Schizophr Bull. 2008 Mar;34(2):375-80. Epub 2007 Jul 18. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk